Entire Portfolio
print

Composition of the portfolio as of March 31, 2014

Celgene   11.9%
Actelion   11.8%
Isis Pharmaceuticals   10.7%
Gilead   9.7%
Incyte   8.7%
Alexion Pharmaceuticals   4.3%
Novo Nordisk   4.1%
Vertex Pharmaceuticals   3.9%
Medivation   3.7%
Synageva BioPharma   3.1%
Halozyme Therapeutics   2.8%
Swedish Orphan Biovitrum   2.7%
Regeneron Pharmaceuticals   2.6%
Pharmacyclics   2.5%
Endocyte   2.3%
Neurocrine Biosciences   1.9%
Immunogen   1.9%
Glenmark Pharmaceuticals   1.3%
Clovis Oncology   1.3%
Alnylam Pharmaceuticals   1.2%
Lupin   1.1%
Theravance   1.1%
Ipca Laboratories   1.1%
Bavarian Nordic   0.8%
Tesaro   0.7%
Radius Health 1)   0.7%
Infinity Pharmaceuticals   0.6%
Puma Biotechnology   0.5
Idenix Pharmaceuticals   0.3%
Probiodrug 1)   0.3%
Achillion Pharmaceuticals   0.2%
Strides Arcolab   0.2%
Ariad Pharmaceuticals   0.1%
     
Cubist Pharmaceuticals Contingent Value Rights - ex Trius   0.0%
Cubist Pharmaceuticals Contingent Value Rights - ex Optimer   <0.1%
Radius Health Warrants 23.04.2018 0.0%   0.0%
Radius Health Warrants 19.02.2019   0.0%
     
Total Securities   CHF 2 258.1 mn
     
Other assets   CHF 25.3 mn
Other payables   CHF (182.4) mn
     
total shareholder's equity   CHF 2 101.0 mn
Treasury shares (in % of company) 2)   4.1%

 

1) Unlisted company

2) Correspond to the total of all own shares held including the second trading line